News

See the latest news about TARA, press releases, videos, and events. We're active in the drug discovery and cardiac toxicology communities, so keep an eye out for conferences we're attending.

Frost & Sullivan Recognizes TARA With 2018 North American Technology Innovation Award

TARA has received Frost & Sullivan’s 2018 North American Technology Innovation Award for our Biowire™ II platform! This award recognizes companies that develop innovative products with rapid market adoption. In addition, it is part of a broader set of Frost & Sullivan’s Best Practices awards presented to companies …

READ MORE

TARA CEO Misti Ushio Named to Fast Company's 100 Most Creative People in Business

New York, (Newswire.com) - TARA Biosystems is proud to announce that TARA CEO Dr. Misti Ushio has been recognized by Fast Company as one of the Top 100 Most Creative People in Business today. The annual list honors an …

READ MORE

TARA Appoints Donna See as Chief Business Officer

New York, (Newswire.com) – TARA Biosystems, Inc., a company offering physiologically human relevant “heart-on-a-chip” tissue models for drug discovery and development applications, announced the appointment of Donna See as Chief Business Officer. In this newly created role, Donna will …

READ MORE

TARA is a Fast Company 2018 World Changing Ideas Finalist

TARA is a Fast Company 2018 World Changing Ideas Award finalist!  The prestigious Fast Company World Changing Ideas Awards honors concepts, designs, business models, products, and companies that inspire, innovate, and solve tough problems that improve personal and global well-being … which is …

READ MORE

TARA Presents at 57th Annual Society of Toxicology (SOT) Meeting

TARA will present a poster at the 57th Annual Society of Toxicology Meeting on March 12. Meet us there to learn about Biowire™ II, our human stem cell-derived “heart-on-a-chip” cardiac tissue platform. Biowire™ II enables precision cardiology efforts for novel heart medicines via its disease modeling and phenotypic screening capabilities. …

READ MORE